Podcast
Drug Discovery AI Talk
Every episode, transcribed and turned into a searchable wiki page — the concepts, entities and tags pulled out of each conversation.
search
69 episodes
EP 69
CollaboFest: Revolutionizing Academic Research
The 2026 SPARC Drug Discovery CollaboFest is redefining academic research by offering focused AI and wet lab services to multidisciplinary teams, bridging the translational gap and turning raw biomedical insights into tangible therapeutic strategies. This episode explores the mission behind CollaboFest and its potential to revolutionize the future of solo academic researchers. With its unique approach to team formation, data-driven decision making, and AI-assisted analysis, CollaboFest is poised to elevate the entire research ecosystem and move the field closer to open source drug discovery 2.0.
CollaboFestAcademic ResearchAI-Driven Drug Discovery
Read wikiarrow_forward
EP 68
Molecular Glues in Therapy
Molecular glues are a new class of drugs that can treat protein interfaces as druggable objects, offering a fundamental rewiring of cellular machinery. This episode explores the world of molecular glues, their mechanism of action, and how AI is being used to design them. With the potential to treat diseases driven by undruggable proteins, molecular glues are redefining what a drug can do inside the human body.
molecular gluesprotein interfacesAI-driven design
Read wikiarrow_forward
EP 67
Does Size Matter?
The podcast discusses the role of large foundation models in drug discovery, comparing their performance to classical machine learning models. The conversation highlights the challenges of working with small, noisy datasets and the importance of understanding the topology of chemical space. The episode explores the trade-offs between exploitation and exploration in drug discovery, and how different models can be used to achieve these goals.
AIdrug discoverymachine learning
Read wikiarrow_forward
EP 66
Quantitative Systems Pharmacology
The FDA is shifting away from relying solely on animal biology in drug development, towards a more complex approach using Quantitative Systems Pharmacology (QSP) and artificial intelligence. QSP is a mathematical framework that simulates the behavior of the human body, allowing for more accurate predictions of drug safety and efficacy. This approach has the potential to reduce and replace animal models in drug development.
Quantitative Systems PharmacologyQSPNew Approach Methodologies
Read wikiarrow_forward
EP 65
Orbiting around Big Pharma
The pharmaceutical industry is undergoing a profound structural shift, with big pharma companies deploying massive supercomputing platforms to accelerate drug discovery. This shift raises concerns about the potential for corporate monopolies and the suppression of unconventional chemistry. In this episode, we explore the implications of this new playbook and the role of academia in maintaining a pluralistic discovery ecosystem.
big pharmaplatform strategydrug discovery
Read wikiarrow_forward
EP 64
Foundation Models in Biomedicine and Drug Discovery
The episode explores the evolution of foundation models in biomedicine and drug discovery, from rigid task-specific models to massive polymath models that learn the fundamental grammar of biology. It discusses the tension between open source and private models, and the rise of agentic AI that can reason and orchestrate virtual labs. The episode also touches on the challenges of simulating complex biological systems and the potential future of clinical trials.
foundation modelsbiomedicinedrug discovery
Read wikiarrow_forward
EP 63
The Era of NAMs
The pharmaceutical industry is undergoing a profound shift in how new medicines are discovered, tested, and validated. The era of New Approach Methodologies (NAMs) is upon us, with a focus on using human biology and artificial intelligence to create a safer and more accurate pipeline for drug development. This episode explores the current state of NAMs, the challenges and limitations of traditional animal testing, and the potential of hybrid approaches that combine physical and computational models.
NAMsNew Approach MethodologiesMicrophysiological Systems
Read wikiarrow_forward
EP 62
Predicting Toxicity
This episode explores the challenges of predicting toxicity in drugs, particularly when it comes to rare liver diseases. Dr. Jake Chen's research highlights the limitations of current AI models and proposes a new framework for predicting toxicity. The discussion delves into the complexities of human biology and the need for a more nuanced approach to drug development.
toxicity predictionAI modelsliver metabolism
Read wikiarrow_forward
EP 61
AI Era Evidence Flywheel
The pharmaceutical industry's initial instinct to use AI as an accelerator has been fundamentally flawed. AI should compress ignorance, not decorate uncertainty. A new approach is needed, focusing on reducing biological uncertainty and using AI to design molecules that fit specific targets.
AIDrug DiscoveryPharmaceutical Industry
Read wikiarrow_forward
EP 60
Cracking the Undruggable Target
Scientists have been trying to crack the code of a notoriously undruggable target in pancreatic cancer for 40 years. Recently, a revolutionary drug called Deraxanracib has shown promising results in clinical trials, offering new hope for patients. This episode delves into the science behind this breakthrough and its potential implications for precision medicine.
pancreatic cancerRAS proteinDeraxanracib
Read wikiarrow_forward
EP 59
Drug Discovery AI Teammates
The future of AI-enabled drug discovery is about massive human teams working seamlessly alongside specialized autonomous teams of AI agents. This episode explores the paradigm shift in drug discovery, from the traditional model of a single principal investigator to a dynamic teaming approach. The discussion delves into the complexity gap in modern drug discovery, the role of AI in bridging this gap, and the importance of human-AI collaboration.
drug discoveryAIhuman-AI collaboration
Read wikiarrow_forward
EP 58
Do We Need Mavericks in AI for Drug Discovery
The podcast explores the role of mavericks in AI for drug discovery, discussing the challenges and opportunities in this field. With a 90% failure rate of drugs in clinical trials, the industry is looking for innovative solutions. The episode delves into the stories of mavericks who are trying to revolutionize AI drug discovery, including Alex Zavornikov, Demis Hassabis, and Aviv Rejev. The conversation also touches on the importance of open-source architectures and the need for a networked coalition to drive progress in this field.
AIdrug discoverymavericks
Read wikiarrow_forward
EP 57
Do You Trust Your AI?
The podcast explores the concept of trust in AI, particularly in the field of medicine and drug discovery. It argues that asking if we trust AI is the wrong question and instead proposes the idea of calibrated reliance. The episode delves into the complexities of AI in biology, highlighting the dangers of data leakage, hallucinated explanations, and the importance of a six-layer trust framework.
AIdrug discoverycalibrated reliance
Read wikiarrow_forward
EP 56
Ethics in AI for Drug Discovery
The use of artificial intelligence in drug discovery is a massive paradigm shift, changing everything from data privacy to biological bias and global security risks. This episode explores the challenges and solutions in this field, including the Good AI Practice Framework and the Ethical Target Product Profile. The goal is to steer this technology toward high social value, producing public health benefits rather than just commercial gain.
AIdrug discoveryethics
Read wikiarrow_forward
EP 55
AI for Drug Patents
The intersection of artificial intelligence and pharmaceutical patents is a complex and highly confusing topic. This episode explores the high stakes and practical realities of how the biotech industry protects its billion-dollar breakthroughs. From the role of human ingenuity in AI-driven labs to the importance of physical proof in patent law, this episode delves into the intricacies of AI patenting and the strategies used by companies to protect their intellectual property.
AIpatent lawpharmaceuticals
Read wikiarrow_forward
EP 54
Companion Diagnostic Biomarkers
This episode explores the world of companion diagnostic biomarkers, which are specialized tests that act as biological bouncers to prevent toxic disasters and match tumors to the right drugs. We delve into the high stakes of pharmacogenetics, where understanding an enzyme like DPYD prevents standard treatments from becoming lethal poisons. We also discuss how multi-gene panels spare patients from unnecessary chemotherapy and how AI is digesting the massive complexities of multi-omics to create hyper-efficient drug pipelines.
companion diagnosticspharmacogeneticsmulti-gene expression panels
Read wikiarrow_forward
EP 53
The Math of AI Drug Discovery
This episode decodes the math behind the hype of AI drug discovery, exploring how companies like Insilico Medicine are using AI to develop new drugs and the financial models that drive their valuation. The discussion delves into the complexities of biotech valuation, including the role of risk-adjusted net present value and the challenges of navigating the 'valley of death' in clinical trials.
AI drug discoverybiotech valuationrisk-adjusted net present value
Read wikiarrow_forward
EP 52
Benchmarking AI for Drug Discovery
This episode explores the world of artificial intelligence in drug discovery, focusing on the importance of benchmarking to measure its success. The discussion delves into the challenges of benchmarking AI models, the issue of benchmark drift, and the need for transparent and robust evaluation methods. The conversation also touches on the potential of agentic AI systems and the future of self-driving labs and digital twins in accelerating drug discovery.
AIDrug DiscoveryBenchmarking
Read wikiarrow_forward
EP 51
OpenClaw for BioPharma
Exploring OpenClaw, a self-hosted AI agent that can execute complex tasks, and its potential to revolutionize biopharma research. OpenClaw is an operational layer that can automate administrative tasks, freeing up human experts to focus on scientific judgment. However, its adoption also raises concerns about security and the need for strict governance.
OpenClawBiopharmaAI
Read wikiarrow_forward
EP 50
Atomic Level Drug Design
This episode explores the concept of atomic level drug design, specifically the Isomorphic Labs Drug Design Engine, and its potential to revolutionize the field of medicine. The discussion delves into the challenges of drug discovery, the importance of understanding the physics of molecular interactions, and the potential of this new technology to find 'secret doors' in proteins and design molecules that can bind to them. The episode also touches on the concept of 'code rot' and the possibility of using this technology to engineer our way out of aging.
drug designprotein structuremolecular interactions
Read wikiarrow_forward
EP 49
From Prompts to Drugs
Imagine a system where you can type a prompt to design a drug, and a machine can create it for you. This episode explores the concept of pharmaceutical superintelligence, where AI and automated labs converge to create new drugs. However, it also delves into the potential risks and limitations of relying on machines for scientific discovery.
pharmaceutical superintelligenceagentic AIhumanoid robots
Read wikiarrow_forward
EP 48
Virtual Clinical Trials
The podcast explores the concept of virtual clinical trials, also known as in silico trials, where experiments are conducted entirely on silicon chips. This approach has the potential to revolutionize the way we test new drugs and treatments, making it faster, cheaper, and more accurate. The episode delves into the different types of virtual clinical trials, including synthetic control arms, quantitative systems pharmacology, and digital twins.
virtual clinical trialsin silico trialsdigital twins
Read wikiarrow_forward
EP 47
The Silicon Alchemist
The story of Alex Zavarankov, a young boy from Riga who grew up to pioneer the use of AI in drug discovery, and his journey from the rubble of the USSR to a massive IPO on the Hong Kong Stock Exchange. This episode explores how AI in drug discovery went from being considered vaporware to putting AI-designed drugs into human clinical trials. The Silicon Alchemist is a story of innovation, perseverance, and the potential of AI to revolutionize the field of medicine.
AIDrug DiscoveryInsilico Medicine
Read wikiarrow_forward
EP 46
Top Ten AI Research Papers in 2025
This episode discusses the top 10 most influential AI for drug discovery papers from 2025, highlighting paradigm shifts in autonomous agents, virtual cell revolution, chemical intelligence, and design proteins beyond nature. The papers represent fundamental changes in the field, accelerating everything, cutting costs, and unleashing synthetic creativity. The episode explores the trends that will dominate 2026 and the impact of AI on drug discovery.
AIDrug DiscoveryAutonomous Agents
Read wikiarrow_forward
EP 45
Genome-wide Virtual Screening
A new AI framework called DreadCLIP is revolutionizing the field of medicine by enabling genome-wide virtual screening. This breakthrough technology has the potential to identify new drug targets and accelerate the discovery of new treatments for diseases. The episode discusses the limitations of traditional molecular docking methods and how DreadCLIP overcomes these challenges. The conversation also explores the potential applications of this technology and its potential to transform the field of medicine.
Genome-wide Virtual ScreeningMolecular DockingContrastive Learning
Read wikiarrow_forward
EP 44
Modern Drug Delivery Platforms
This episode explores the cutting edge of drug delivery systems, where medicine is moving from traditional formulae to fully programmable systems. The core theme is how artificial intelligence acts as the glue that holds this new paradigm together. The discussion covers the core technical hurdles, including bio-distribution control, intracellular trafficking, manufacturability, and scaling, as well as translation across species.
drug deliveryartificial intelligencelipid nanoparticles
Read wikiarrow_forward
EP 43
Antibody-Drug Conjugate
Antibody-Drug Conjugates (ADCs) are a type of cancer treatment that combines a monoclonal antibody with a cytotoxic payload. This episode explores the history, mechanics, and cutting-edge technology behind ADCs, including their potential to revolutionize oncology. With 21 approved ADCs worldwide and a market projected to hit over $30 billion by 2028, ADCs are a rapidly growing field. This episode delves into the complexities of ADC design, including the balancing act between stability and release, and the role of AI in accelerating ADC development.
Antibody-Drug ConjugateCancer TreatmentOncology
Read wikiarrow_forward
EP 42
Biologic Immunogenecity
Biologics have revolutionized modern medicine, but they carry a silent risk called immunogenicity, where the patient's immune system sees the therapeutic protein as foreign. This episode delves into the factors that drive this immune response and the sophisticated testing required to mitigate it. The consequences of immunogenicity can be disastrous, leading to treatment failure, safety issues, and pharmacokinetic problems.
biologicsimmunogenicityanti-drug antibodies
Read wikiarrow_forward
EP 41
CAR T Cell Therapy
CAR T cell therapy is a revolutionary treatment that uses a patient's own immune cells to fight cancer. It has shown remarkable success in treating blood cancers, but its high cost and complexity make it inaccessible to many. Researchers are working to improve the therapy and make it more affordable.
CAR T cell therapyimmunotherapycancer treatment
Read wikiarrow_forward
EP 40
AI-Guided Alzheimer's Trial Design Lessons
This episode explores the challenges of Alzheimer's disease treatment and how artificial intelligence is being used to improve trial design and patient outcomes. The discussion covers recent trials, including donanumab and semaglutide, and the importance of mechanistic precision and biomarker-guided stratification. The role of AI in rescuing failed drugs and optimizing trial logistics is also examined.
Alzheimer's diseaseartificial intelligencetrial design
Read wikiarrow_forward
EP 39
AI Drug Discovery Career Roadmap: Anti-Fragile Skills
The convergence of artificial intelligence and drug discovery is reshaping the global job market. This episode provides a roadmap for building a durable career in this field, focusing on anti-fragile skills that are resilient to automation. The discussion covers the market reality, key skill types, and the importance of cognitive, scientific, and technical skills. The goal is to help listeners structure their skills to thrive in this changing landscape.
AIMachine LearningDrug Discovery
Read wikiarrow_forward
EP 38
US and China Rivalry in Biotech
The US and China are engaged in a fierce rivalry in the biotech industry, with China's speed and scale threatening to upend the US's traditional dominance. The rivalry is driven by China's strategic government prioritization, massive patient population, and highly centralized hospital networks. The US still has an edge in deep algorithmic innovation and computational power, but China's data scale and deployment speed are giving it an advantage in AI.
biotechUS-China rivalryartificial intelligence
Read wikiarrow_forward
EP 37
Open Source Drug Discovery 2.0
The current system of drug discovery is slow and expensive, with the cost of developing a new drug doubling every nine years. Open Source Drug Discovery 2.0 (OSDD2) is a potential solution, using a combined sociotechnical and economic approach to democratize early-stage research and make it more efficient. The OSDD2 model is designed to tackle the failures of the first wave of open source drug discovery, including lack of funding, unclear intellectual property, and no clear path to market.
Open Source Drug DiscoveryEroom's LawRelay Model
Read wikiarrow_forward
EP 36
Future of IND Filings
The use of AI and machine learning in regulatory affairs is revolutionizing the process of getting new medicines approved. From speeding up submissions to monitoring compliance and safety, AI is making the process faster, more efficient, and safer. In this episode, we dive deep into how AI is changing the rules of regulatory affairs and what it means for the future of drug development.
AIRegulatory AffairsIND Filings
Read wikiarrow_forward
EP 35
AI-Driven Drug Repurposing
The pharmaceutical industry is known for its long and expensive drug development process. However, AI-driven drug repurposing is changing the game by finding new uses for existing drugs, reducing the time and cost of bringing new treatments to patients. This approach has already shown promising results, including the rapid identification of baricitinib as a potential treatment for COVID-19. In this episode, we explore the technologies behind AI-driven drug repurposing, including machine learning, deep learning, knowledge graphs, and natural language processing.
AIdrug repurposingmachine learning
Read wikiarrow_forward
EP 34
AI Agents Transform Drug Discovery
AI agents are revolutionizing the field of drug discovery by speeding up the process and making it more efficient. However, their success is limited by the quality and quantity of the data available to train predictive models. This episode explores the potential of AI agents in drug discovery and the challenges they face, including data scarcity and the need for human expertise.
AI AgentsDrug DiscoveryPredictive Models
Read wikiarrow_forward
EP 33
Modern Therapeutic Modalities
The podcast discusses the new therapeutic toolkit, including engineered cells, genetic instructions, and digital design. It highlights the shift in market power towards biologics and the role of artificial intelligence in linking different approaches together. The episode also explores the diversification of therapeutic modalities, including gene editing, cell therapy, and RNA therapies.
gene editingcell therapyRNA therapies
Read wikiarrow_forward
EP 32
AI Drug Discovery Startups
The podcast explores the intersection of artificial intelligence and pharmaceutical research, discussing how AI is revolutionizing the drug discovery process. With the potential to significantly reduce the time and cost of bringing new drugs to market, AI-driven drug discovery is becoming increasingly important. The episode delves into the science behind AI-driven drug discovery, the competing business models, and the global race for dominance in this field.
AIDrug DiscoveryPharmaceutical Research
Read wikiarrow_forward
EP 31
Neuroendocrine Peptide Analogs
This episode explores the world of neuroendocrine peptides, the body's own signaling molecules that bridge the nervous system and endocrine functions. From the early days of insulin to the latest advancements in peptide engineering, we delve into the challenges and successes of using these molecules as drugs. With over 80 peptide drugs on the market, the field has seen massive growth in recent years, and we examine the key factors driving this progress.
neuroendocrine peptidespeptide engineeringinsulin analogs
Read wikiarrow_forward
EP 30
Autism Data Science Initiative: Unlocking Precision Treatment
The Autism Data Science Initiative is driving radical change in understanding and treating autism spectrum disorder. This episode explores the latest research in etiology, diagnosis, and personalized care models. With the help of data science and AI, diagnosis is shifting from subjective observation to objective measurement, and care models are becoming more personalized and accessible.
autismdata scienceAI
Read wikiarrow_forward
EP 29
Cystic Fibrosis: A Blueprint for Rare Disease Cures
Cystic fibrosis was once a devastating diagnosis, but thanks to 30 years of painstaking science, bold strategy, and intense collaboration, it's now a manageable chronic condition. This episode explores the key scientists, funding models, and breakthroughs that made this transformation possible. The story of cystic fibrosis serves as a blueprint for tackling other rare diseases, with lessons on empowered patient advocacy, innovation in research tools, and sustained focus.
cystic fibrosisrare diseasegenetic disease
Read wikiarrow_forward
EP 28
Eroom's Law
The pharmaceutical industry is facing a paradox: despite scientific progress, drug discovery is getting slower and more expensive. This episode explores the challenges and innovations in the industry, including the role of intellectual property rights, the impact of pandemics, and the need for new antibiotics. The industry's economic footprint is also significant, contributing to global GDP and creating jobs.
pharmaceutical industrydrug discoveryinnovation
Read wikiarrow_forward
EP 27
Druggability and AI
The concept of druggability is evolving with the help of AI and new therapeutic modalities. This episode explores how science is expanding what's possible and making the process more efficient and precise. From traditional small molecules to biologics and RNA therapeutics, new approaches are being developed to tackle previously undruggable targets. AI is playing a crucial role in accelerating and improving the drug discovery process, from identifying potential targets to designing new molecules.
druggabilityAIbiologics
Read wikiarrow_forward
EP 26
AI for Combination Drug Therapy
This episode explores the use of artificial intelligence in designing combination drug therapies, discussing the benefits and challenges of this approach, and examining the role of AI in optimizing treatment outcomes. The conversation delves into the complexities of combination therapy, including the distinction between additive and synergistic effects, and the importance of considering toxicity, cost, and regulatory hurdles. The episode aims to provide a comprehensive understanding of the current landscape and future potential of AI-driven combination drug therapy.
combination therapyartificial intelligenceadditivity
Read wikiarrow_forward
EP 25
#25. Overall Survival Focus and AI Oncology Drugs
The FDA's new guidance prioritizes overall survival as the primary endpoint in cancer drug approval, marking a significant shift in cancer drug development. This episode explores the implications of this change and the role of AI in meeting the new standards. With a focus on patient-centered outcomes, the FDA's guidance demands therapies that genuinely extend and improve lives, rather than just shrinking tumors. AI-driven drug discovery is poised to play a crucial role in this new era, enabling the design of better drug candidates, prediction of outcomes, and simulation of trials.
cancer drug developmentoverall survivalAI-driven drug discovery
Read wikiarrow_forward
EP 24
#24. Digital Twins: Transforming Clinical Trials
The use of digital twins in clinical trials is transforming the way drugs are developed, making the process smarter, faster, and more precise. This technology has the potential to reduce the need for placebo groups, speed up drug development, and get treatments to patients faster. However, it also raises important questions about the reliability and ethics of virtual patients.
digital twinsclinical trialspharmacology
Read wikiarrow_forward
EP 23
AI and the Decentralization of Drug Discovery
The episode explores how AI is revolutionizing the drug discovery process by decentralizing it, making it more accessible and affordable for smaller groups and individuals. AI technologies like generative AI and agentic models are driving this shift, enabling the design of novel drug candidates and automating experiments. The episode also discusses the challenges and limitations of this approach, including the need for open infrastructure and data, funding reform, and new incentives for data sharing.
AIdrug discoverydecentralization
Read wikiarrow_forward
EP 22
Molecular Glue Degraders
Molecular glue degraders are a revolutionary approach in drug discovery, using the cell's own systems to get rid of disease-causing proteins. This episode explores how these molecules work, their potential in treating various diseases, and the role of AI in their discovery and design. With the ability to target previously undruggable proteins, molecular glue degraders are opening up new doors in the treatment of cancer, neurodegenerative diseases, autoimmune diseases, and infectious diseases.
molecular glue degraderstargeted protein degradationartificial intelligence
Read wikiarrow_forward
EP 21
N-of-1: The Future of Personalized Drug Development
The convergence of artificial intelligence and N-of-1 clinical trials is revolutionizing drug discovery and personalized medicine. This approach allows for the design of medications tailored to individual patients, rather than the traditional one-size-fits-all method. By leveraging AI and N-of-1 trials, researchers can speed up drug discovery, fine-tune treatments, and improve patient outcomes. This episode explores the potential of this innovative approach and its implications for the future of healthcare.
personalized medicineN-of-1 clinical trialsartificial intelligence
Read wikiarrow_forward
EP 20
Ensifentrine's Triumph: An AI Blueprint for Drug Development
Verona Pharma's journey with Ensifentrine offers a blueprint for drug development, leveraging AI to de-risk and speed up the process. Ensifentrine, a dual inhibitor, targets PDE3 and PDE4 enzymes, providing a dual therapeutic punch for COPD treatment. The company's strategic moves, including a nebulized inhalation suspension delivery method, helped the drug achieve a broad FDA label and significant commercial success.
COPDEnsifentrineVerona Pharma
Read wikiarrow_forward
EP 19
AI Agents: Transforming Drug Discovery through Collaborative Partnerships
This episode explores how AI agents are transforming drug discovery through collaborative partnerships with human researchers. AI is accelerating processes, generating insights, and streamlining operations, from hypothesis generation to precision information access and automating regulatory submissions. The synergy between human and artificial intelligence is undeniable, and the question is how thoughtfully we integrate AI to ensure cures are developed and distributed with equity and accountability.
AIDrug DiscoveryCollaborative Partnerships
Read wikiarrow_forward
EP 18
First-in-Class vs. Best-in-Class AI Drug Discovery Strategies
The podcast explores the impact of AI on drug discovery, discussing first-in-class and best-in-class strategies, and how AI is changing the game. With the potential to significantly reduce costs and increase success rates, AI is revolutionizing the pharmaceutical industry. However, there are still challenges to overcome, including trust issues and regulatory hurdles.
AIdrug discoverypharmaceuticals
Read wikiarrow_forward
EP 17
Atul Butte: Pioneer of Data-Driven Medicine
Professor Atul Butte's legacy is a testament to the power of data-driven medicine. As a pioneer in the field, he reshaped how we think about data in medicine, connecting computational findings to clinical applications. His work has inspired a new generation of researchers and entrepreneurs to push the boundaries of what is possible. This episode explores his journey, from his early days in coding to his groundbreaking work in translational bioinformatics, and how his vision continues to drive innovation in the field.
Data-Driven MedicineTranslational BioinformaticsComputational Drug Repurposing
Read wikiarrow_forward
EP 16
Can AI Scientists Revolutionize Drug Discovery
This episode explores the potential of AI in revolutionizing drug discovery, a process that traditionally takes 12 to 15 years and is fraught with complexity and cost. AI models are being customized for drug discovery tasks, offering exciting possibilities for accelerating the process. However, limitations and challenges, including safety concerns and regulatory frameworks, need to be addressed.
AIDrug DiscoveryScience
Read wikiarrow_forward
EP 15
AAV 2.0: Next-Generation Gene Therapy Vectors
This episode explores the revolutionary area of gene therapy, specifically adeno-associated virus (AAV) and its evolution into AAV 2.0. AAV has become a promising tool in drug development, especially with the involvement of artificial intelligence. The discussion delves into the accidental beginnings of AAV, its first big wins, significant barriers, and what's next for AAV 2.0. It highlights how AI is transforming the design and manufacturing of next-generation vectors, addressing previous limitations and opening new possibilities for gene therapy.
Gene TherapyAdeno-Associated Virus (AAV)AAV 2.0
Read wikiarrow_forward
EP 14
Global Trial & Error: Can AI Help?
The FDA's recent decision to not expand the use of Columbia, a lymphoma treatment, has raised questions about the complexity of evaluating global trials. This episode explores the reasons behind the decision and how AI can help navigate these challenges. The discussion delves into the biological heterogeneity of the disease, pharmacokinetic differences, and inconsistencies in trial conduct, highlighting the need for better tools to handle this complexity.
AI in clinical trialsbiological heterogeneitypharmacokinetic differences
Read wikiarrow_forward
EP 13
Chemical Space Docking: Is Bigger Better?
This episode explores the concept of chemical space docking, a strategy used in drug discovery to navigate the vast theoretical space of potential drug-like molecules. The discussion delves into the challenges and advantages of larger virtual libraries in finding better drug candidates. The episode also touches on the importance of intelligent filtering and the potential for unforeseen discoveries in the mostly unexplored molecular realms.
chemical space dockingdrug discoveryvirtual libraries
Read wikiarrow_forward
EP 12
Can AI Help Develop the Next-Generation Diabetes Drug?
This episode explores the potential of AI in developing the next-generation diabetes drug, focusing on the protein TXNIP as a promising target. Current treatments for diabetes manage the condition but don't address the root cause of beta-cell loss. Targeting TXNIP could offer a new strategy for preserving beta-cell function. However, developing drugs that effectively and safely target TXNIP poses significant technical challenges, including designing small molecules that can bind to TXNIP's flat protein interaction surfaces and ensuring the molecules can cross cell membranes and avoid being pumped back out.
diabetesTXNIPAI
Read wikiarrow_forward
EP 11
TYK2 Inhibitor Landscape and Pipeline
A new psoriasis treatment, zesacitinib, has been developed using artificial intelligence and is potentially 1.7 million times more precise than current treatments. This episode explores the development and potential impact of zesacitinib, as well as the broader landscape of TYK2 inhibitors and the role of AI in drug discovery.
TYK2 inhibitorsAI-powered drug designpsoriasis
Read wikiarrow_forward
EP 10
Biomedical Research Funding and Innovation
The US Senate Appropriations Committee hearing on biomedical research funding highlights the importance of stable funding for innovation and health. The hearing discussed the impact of funding on research, patient stories, and the role of the FDA. The episode explores the complexities of biomedical research, including funding debates, regulatory oversight, and global politics.
biomedical researchfundinginnovation
Read wikiarrow_forward
EP 9
Patent Dispute and Protections in the New AI Era
The USPTO's decision to invalidate Pharmacyclics' patent has significant implications for cancer drug development. This episode explores the patent dispute between Pharmacyclics and Beijing, and what it means for the future of drug development. The discussion delves into the complexities of patent law, the role of AI in drug discovery, and the importance of a strategic, multi-layered patent approach.
patent lawBTK inhibitorsAI in drug discovery
Read wikiarrow_forward
EP 8
Immune Response, Vaccines, and Autism
This episode explores the scientific evidence surrounding the potential link between vaccines and autism, examining the research and consensus on the topic. The discussion delves into the immune system, genetic factors, and vaccine components to understand the complex relationship between vaccines and autism. The goal is to provide an unbiased review of the science, addressing concerns and misconceptions.
vaccinesautismimmune system
Read wikiarrow_forward
EP 7
FDA Roadmap: Reducing Animal Testing in Preclinical Studies
The FDA proposes a roadmap to reduce animal testing in preclinical studies, aiming to improve drug development efficiency and accuracy. This episode discusses the limitations of traditional animal testing and the potential of new approach methodologies (NAMs) like in vitro human-based systems and in silico modeling. The FDA's plan to implement NAMs and the challenges ahead are also explored.
FDAanimal testingpreclinical studies
Read wikiarrow_forward
EP 6
AI in Drug Discovery - Reality Check
The potential of AI in drug discovery is vast, but what are the real barriers to its success? This episode explores the excitement and caution surrounding AI's role in revolutionizing health and curing diseases. With commentary from Derek Lowe, we delve into the limitations of current AI technology and the importance of fundamental biological knowledge. From protein structures to the complexity of biology, we examine the tension between the incredible potential of AI and the daunting reality of what we still don't know.
AIDrug DiscoveryProtein Structures
Read wikiarrow_forward
EP 5
GLP-1 Medications: Current Status and Future Metabolic Therapies
This episode explores the current status and future of GLP-1 medications, which have revolutionized the treatment of metabolic diseases such as diabetes and obesity. The discussion covers the science behind these medications, their effectiveness, and the potential for future advancements. With millions of people using these medications, the episode delves into the reasons behind their popularity and the potential for new therapies to emerge.
GLP-1 medicationsmetabolic diseasesobesity
Read wikiarrow_forward
EP 4
Alzheimer's Drug Development: Mechanisms, IP, and the Evolving Landscape
This episode explores the complex landscape of Alzheimer's drug development, including the science behind the disease, current treatments, and the challenges researchers face. Our expert guest discusses the role of intellectual property in driving innovation and the various approaches being explored to tackle this devastating disease.
Alzheimer's diseasedrug developmentintellectual property
Read wikiarrow_forward
EP 3
FDA Guidance: AI in Drug and Biological Product Regulatory Decisions
The FDA's new draft guidance on the use of artificial intelligence in drug development has significant implications for the industry. This episode breaks down the guidance and explores its potential impact on regulatory decisions. The FDA's risk-based credibility assessment framework is a key component of the guidance, and understanding it can help companies navigate the regulatory landscape.
FDAAIdrug development
Read wikiarrow_forward
EP 2
2024 Fierce 50: Innovations and Breakthroughs in Biopharma
The 2024 Fierce 50 Honorees in Biopharma and Healthcare are driving innovation and breakthroughs in areas like AI, genomics, precision oncology, and more. This episode explores the key trends and innovations in biopharma, including the use of AI in drug discovery and healthcare delivery. The discussion also covers advancements in genomics, precision oncology, and immunotherapy, as well as major therapeutic breakthroughs in areas like diabetes, obesity, and Alzheimer's disease.
biopharmainnovationAI
Read wikiarrow_forward
EP 1
AI Drug Discovery in 2025
This episode explores the potential impact of a second Trump administration and Robert F. Kennedy Jr.'s role in health agencies on AI drug discovery. The discussion covers possible policy shifts, leadership changes, and their effects on the industry. The episode delves into the potential benefits and drawbacks of these changes, including increased autonomy, deregulation, and funding uncertainty.
AIDrug DiscoveryRegulatory Environment
Read wikiarrow_forward